-
2024-518771-66-00
9
2025-07-01
Hepatoblastoma, Rhabdomyosarcoma
-
2024-512696-12-00
4
2025-06-24
BCR-ABL1+ Chronic Myeloid Leukemia
-
2025-520705-12-00
4
2025-06-24
Colitis Ulcerative
-
2024-520167-13-00
5
2025-06-17
Immunoglobulin A Nephropathy
-
2024-513122-27-00
5
2025-06-10
Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or
-
2023-509391-42-00
11
2025-06-02
Chron's Disease
-
2024-517432-21-00
4
2025-05-30
Gynecological Cancers
-
2024-517812-31-00
6
2025-05-21
Haemophilia A
-
2024-517513-32-00
5
2025-05-16
Sjögren’s Syndrome
-
2023-510155-37-00
5
2025-05-08
Hypomethylating agent (HMA) naive myelodysplastic syndromes
Myelodyspl
-
2023-506460-14-00
5
2025-05-07
Chronic kidney disease (CKD) and hypertension.
-
2024-516009-22-00
5
2025-04-30
myelodysplastic neoplasms/syndromes (MDS)
-
2024-516030-35-00
5
2025-04-30
Multiple myeloma
-
2024-515279-37-00
5
2025-04-17
Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
-
2024-515989-14-00
4
2025-04-17
Nevoid Basal Cell Carcinoma Syndrome
-
2024-511495-32-00
5
2025-04-16
Chronic Phase Chronic Myeloid Leukemia
-
2024-513053-69-00
5
2025-04-16
Moderately to Severely Active Crohn's Disease (CD)
-
2023-506206-38-00
4
2025-04-09
Diffuse Large B-cells non-Hodgkin Lymphoma
-
2024-513550-30-00
5
2025-03-28
Newly diagnosed Glioblastoma
-
2024-515252-20-00
9
2025-03-14
Myelofibrosis (MF) unresponsive to JAK inhibitors
-
2024-514594-21-00
5
2025-03-13
Heterozygous Familial Hypercholesterolemia
-
2024-513443-93-00
4
2025-03-10
Recurrent Meningioma without local treatment options (Surgery or Radio
-
2024-514306-31-00
5
2025-02-13
Pyoderma gangrenosum
-
2024-519514-31-00
4
2025-01-31
metastatic triple-negative PD-L1 positive breast cancer